On or around 04/18/2018 (Court's order of dismissal)
Filing Date: December 29, 2017
According to the Complaint, on December 12, 2017, Repros and Allergan issued a joint press release announcing that they had entered into a definitive agreement (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Acquisition Sub will commence a cash tender offer to acquire all of the issued outstanding shares of Repros common stock for $0.67 per share (the “Offer Price”).
The Complaint alleges that on December 29, 2017, in order to convince Repros stockholders to tender their shares, the Board authorized the filing of a materially incomplete and misleading Schedule 14D- 9 Solicitation/Recommendation Statement (the “14D-9”) with the Securities and Exchange Commission (“SEC”). In particular, the 14D-9 contains materially incomplete and misleading information concerning: (i) financial projections for the Company; and (ii) the valuation analyses performed by the Company’s financial advisor, Stifel, Nicolaus & Company, Incorporated (“Stifel”), in support of their fairness opinions.
This case was voluntarily dismissed as moot on April 16, 2018.
Company & Securities Information
Defendant: Repros Therapeutics Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: RPRX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Mark Neuterman, et al. v. Repros Therapeutics Inc., et al.
COURT: S.D. Texas
DOCKET #: 17-CV-03918
JUDGE: Hon. Kenneth M Hoyt
DATE FILED: 12/29/2017
CLASS PERIOD START: 12/12/2017
CLASS PERIOD END: 12/29/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Monteverde & Associates PC 350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118 (212) 971-1341 ·